Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer
Vidar Staalesen, Beryl Leirvaag, Johan Richard Lillehaug, et al.
Journal of Obesity
|
March 16, 2011
Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents
Bodil Bjørndal, Lena Burri, Vidar Staalesen, et al.
Journal of Obesity
|
January 29, 2011
Tissue-specific effects of bariatric surgery including mitochondrial function
Simon N Dankel, Vidar Staalesen, Bodil Bjørndal, et al.
Biochimica Et Biophysica Acta
|
January 19, 2010
Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity
Elisabet Ognedal Berge, Vidar Staalesen, Anne Hege Straume, et al.
International Journal of Cancer
|
April 20, 2007
Mutations and polymorphisms of the p21B transcript in breast cancer
Stian Knappskog, Ranjan Chrisanthar, Vidar Staalesen, et al.
Oncogene
|
September 14, 2004
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
Vidar Staalesen, Jacob Falck, Stephanie Geisler, et al.
Molecular Cancer
|
July 3, 2010
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
Elisabet Ognedal Berge, Stian Knappskog, Stephanie Geisler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2006
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Vidar Staalesen, Stian Knappskog, Ranjan Chrisanthar, et al.
Molecular Oncology
|
May 26, 2015
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Stian Knappskog, Elisabet O Berge, Ranjan Chrisanthar, et al.
Cancer Cell
|
February 15, 2011
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Stian Knappskog, Merete Bjørnslett, Line M Myklebust, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer
Vidar Staalesen, Beryl Leirvaag, Johan Richard Lillehaug, et al.
Journal of Obesity
|
March 16, 2011
Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents
Bodil Bjørndal, Lena Burri, Vidar Staalesen, et al.
Journal of Obesity
|
January 29, 2011
Tissue-specific effects of bariatric surgery including mitochondrial function
Simon N Dankel, Vidar Staalesen, Bodil Bjørndal, et al.
Biochimica Et Biophysica Acta
|
January 19, 2010
Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity
Elisabet Ognedal Berge, Vidar Staalesen, Anne Hege Straume, et al.
International Journal of Cancer
|
April 20, 2007
Mutations and polymorphisms of the p21B transcript in breast cancer
Stian Knappskog, Ranjan Chrisanthar, Vidar Staalesen, et al.
Oncogene
|
September 14, 2004
Alternative splicing and mutation status of CHEK2 in stage III breast cancer
Vidar Staalesen, Jacob Falck, Stephanie Geisler, et al.
Molecular Cancer
|
July 3, 2010
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
Elisabet Ognedal Berge, Stian Knappskog, Stephanie Geisler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2006
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Vidar Staalesen, Stian Knappskog, Ranjan Chrisanthar, et al.
Molecular Oncology
|
May 26, 2015
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Stian Knappskog, Elisabet O Berge, Ranjan Chrisanthar, et al.
Cancer Cell
|
February 15, 2011
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Stian Knappskog, Merete Bjørnslett, Line M Myklebust, et al.
Page
of 1